Abstract
Clinical data have supported the combination of subcutaneous r-interleukin-2 (rIL-2) and r-interferon-alpha (rIFN-alpha) as a promising combination for advanced renal cell carcinoma (RCC), with a reduced toxicity. We evaluated the activity and safety of this outpatient immunotherapy and report on the clinical results and the long-term survival analysis. Objective responses was observed in 9 of 50 (18%) patients, 6 of whom (12%) achieved a complete response. Overall median survival is 12 months, six patients were surviving at a median follow-up of 24 months, and three (6%) are still progression-free.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Multicenter Study
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / secondary
-
Female
-
Humans
-
Immunotherapy, Active*
-
Injections, Subcutaneous
-
Interferon alpha-2
-
Interferon-alpha / administration & dosage*
-
Interferon-alpha / therapeutic use
-
Interleukin-2 / administration & dosage*
-
Interleukin-2 / therapeutic use
-
Kidney Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Prognosis
-
Recombinant Proteins
-
Remission Induction
-
Survival Analysis
Substances
-
Interferon alpha-2
-
Interferon-alpha
-
Interleukin-2
-
Recombinant Proteins